Shanghai Fuhong Hanlin Biotechnology Co., Ltd. is a Chinese company mainly engaged in the research, development, production and sales of monoclonal antibody products. The company's main products include rituximab injection HLX01 (Hanlikang), Herceptin (trastuzumab) bioanalogue HLX02, trimethoprim (adamumab) bioanalogue HLX03 and Avetine (bevacizumab) bioanalogue HLX04, as well as candidate biological innovation drugs. It includes HLX06 (a new type of VEGFR2 inhibitor), HLX07 (a kind of EGFR inhibitor), HLX10 (a new type of PD-1 inhibitor), HLX20 (a new type of PD-L1 inhibitor) and HLX22 (a new type of HER2 inhibitor). The company also provides related technical services. The company mainly operates in China and the United States.
CEO： Wenjie Zhang
Market： Hong Kong motherboard